A new study of pediatric patients from researchers at the Perelman School of Medicine at the University of Pennsylvania shows that precise targeting and limited dosing of radiation via proton therapy proves to be an advantage in ongoing efforts to reduce treatment side effects among head and neck cancer patients.
Standard (x-ray) radiation treatment and proton therapy are significantly different. Sufficient…Continue
Added by Editorial Team on September 24, 2013 at 3:30pm — No Comments
A highly targeted cancer radiation therapy called stereotactic body radiotherapy or SBRT may offer a safe and effective treatment option for elderly pancreatic cancer patients unable to undergo surgery or combined chemotherapy and radiation therapy, according to researchers at Henry Ford Hospital in Detroit.
A stereotactic radiation treatment is a method of giving radiation that can be highly targeted to the tumor,…Continue
Added by Editorial Team on September 24, 2013 at 8:30am — No Comments
It is estimated that as many as 96% of men with testicular cancer survive at least ten years from diagnosis , but more advanced forms need to be treated with combination chemotherapy – which can have serious long-term complications. To reduce these long-term complications, researchers have been searching for new treatments that would reduce the risk of relapse after initial treatment and so spare as many men as possible from needing combination chemotherapy.
Added by Editorial Team on August 16, 2013 at 7:30am — No Comments
ASCO President Sandra M. Swain, MD, FACP, introduces various study related to breast cancer research presented during the 49th Annual Meeting of the American Society of Clinical Oncology, being held in Chicago, May 31 - June 4, 2013.
Added by Editorial Team on June 3, 2013 at 5:30pm — No Comments
Results from a recent, phase III, randomized clinical trial, supported, in part, the National Cancer Institute and Amgen, shows that low-dose weekly administration of adjuvant paclitaxel (Taxol®, Bristol-Myers Squibb Company) vs. standard, every two weeks administration in women with higher-risk…Continue
Added by Editorial Team on June 3, 2013 at 12:30pm — No Comments
A survey of 250 U.S. oncologists and hematologists finds that more than 80% of practicing oncologists and hematologists have encountered cancer drug shortages between March and September of 2012. Many of the doctors involved in the management and care of patients with cancer reported that these shortages affected the quality of patient care that doctors were able to provide. The study also found that the cost of care was driven upward because physicians were forced to substitute more…Continue
Added by Editorial Team on June 3, 2013 at 7:30am — No Comments
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard chemotherapy who received the drug bevacizumab (Avastin®; Genentech/Roche) lived 3.7 months longer than patients who did not receive the drug according to findings from a large, randomized Phase III clinical trial (GOG240).
These results were released, based on an interim analysis, in February 2013, and updates were presented today by Krishnansu Sujata Tewari, MD, a professor…Continue
Added by Editorial Team on June 2, 2013 at 5:30pm — No Comments
The randomized phase III DECISION study, which was supported in part by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, finds that the targeted drug sorafenib (Nexavar®; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals) stalls disease progression by five months in patients with locally advanced or metastatic differentiated thyroid cancer or DTC that has progressed despite standard radioactive iodine (RAI) therapy. The…Continue
Added by Editorial Team on June 2, 2013 at 8:30am — No Comments
A phase III clinical trial in women with advanced ovarian cancer, supported by GlaxoSmithKline (GSK), finds that treatment with the oral targeted drug pazopanib (Votrient, GSK) following initial successful chemotherapy extends disease-free survival by an average of 5.6 months, compared to…Continue
Added by Editorial Team on June 1, 2013 at 9:00am — No Comments
Phase III clinical trial results from PRELUDE study, which explored the enzastaurin (Eli Lilly and Company; Lilly Oncology) as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL), failed to show a statistically significant increase compared to placebo…Continue
Added by Peter Hofland, PhD on May 10, 2013 at 6:00am — No Comments
Nearly one third of all patients diagnosed with colorectal cancer (CRC) are diagnosed with metastatic disease or Stage IV disease. If surgical resection of the (liver) metastases is not possible in these cases and the lesion or lesions are considered inoperable, there limited liver directed treatment options available.
New results from a phase III clinical trial conducted in Shanghai, China, shows that adding cetuximab (…Continue
Added by Editorial Team on April 8, 2013 at 9:00pm — No Comments
Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease. Reporting the results of a first-of-its-kind phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by researchers from the Fred Hutchinson Cancer Research Center found that giving patients high doses of Vorinostat (suberoylanilide hydroxamic…Continue
Added by Peter Hofland, PhD on February 4, 2013 at 10:00pm — No Comments
Women undergoing chemotherapy who experience cognitive problems, commonly referred to as “chemo brain,” displayed alterations in neurocognitive responses prior to undergoing treatment, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held from December 4-8 in San Antonio, Texas.
Bernadine Cimprich, Ph.D., R.N., associate professor emerita at the…Continue
Added by Editorial Team on December 7, 2012 at 4:30pm — No Comments
A large study reports that a new real-time performance tracking system, which monitors adherence to five National Quality Forum endorsed quality care metrics for breast and colon cancer, significantly improved quality standard adherence rates over a four-year period in a group of 64 cancer centers participating in the Rapid Quality Reporting System or RQRS “beta test.” Use of the system also reduced reported…Continue
Added by Peter Hofland, PhD on November 27, 2012 at 6:30pm — No Comments
A large population- and health systems-based prospective study reports earlier discussions about end of life (EOL) care preferences are strongly associated with less aggressive care in the last days of life and increased use of hospice care for patients with advanced cancer. The study, published November 13, 2012 issue of the Journal of Clinical Oncology, provides the first-of-its –kind scientific evidence that timing of End of…Continue
Added by Editorial Team on November 13, 2012 at 2:00pm — No Comments
New findings that highlight the challenges of managing thromboembolic events in patients being treated for cancer were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012).
Venous thromboembolism causes symptoms in about 3 to 4% of cancer patients whose chemotherapy drugs are delivered via a central venous catheter, commented Fausto Roila, M.D. from Medical Oncology Department, Terni,…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 9:30pm — No Comments
The results of a new phase III head-to-head study comparing crizotinib, a targeted therapy, with standard chemotherapy show that crizotinib is more effective than standard chemotherapy for patients with advanced, ALK-positive lung cancer. The results were prensented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna, Austria (September 28 - October 2, 2012).…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 6:00am — No Comments
Earlier this week the first patient has been dosed in a Phase Ib/IIa study of CRLX101 (formerly called IT-101, Cerulean Pharma Inc.), dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in combination with bevacizumab (Avastin®, Genentech/Roche) in metastatic renal cell carcinoma (mRCC) patients. Cerulean also announced the completion of enrollment of its randomized Phase II study in advanced non-small…Continue
Added by Peter Hofland, PhD on July 2, 2012 at 7:00pm — No Comments
The Death of his first wife makes improving the Quality of Life (QoL) for patients with a brain tumor very personal for Mike Robbins, associate director of the Thomas K. Hearn Jr. Brain Tumor Research Center at Wake Forest Baptist Medical Center. Robbins knows all too well that the likely outcome when patients are diagnosed with brain tumors that are "high grade" may not always be positive.
Added by Peter Hofland, PhD on June 26, 2012 at 11:00am — No Comments
Results from the phase III CLEOPATRA study showed that women with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of pertuzumab (Perjeta™, Genentech/Roche), trastuzumab (Herceptin®, Genentech/Roche) and docetaxel chemotherapy, compared to trastuzumab and docetaxel chemotherapy alone. in the Phase III . These data will be submitted for presentation at an upcoming medical meeting.…
Added by Peter Hofland, PhD on June 21, 2012 at 5:30pm — No Comments